NextBio

Help
Description: An antilipemic agent which reduces both cholesterol and triglycerides in the blood. [PubChem]
Drug Type: Small Molecule; Approved
Pharmacology: Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Mechanism of Action: Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.
Indication: For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Half Life: 20 hours
View Complete Description



Data Correlations | 9 studies

Help for Data Correlations View All
Genes category icon Genes
Score Help
PPARA 100 100
545481 100 100
ACOT1 94 94
XIRP1 93 93
EHHADH 89 89
CIDEA 88 88
View Top Genes
Biogroups category icon Biogroups
Score Help
PPAR Signaling Pathway 100 100
Fatty Acid Metabolism 97 97
Beta-Oxidation of Fatty Acids 96 96
PPAR-a Pathway 96 96
Cyclin E Destruction Pathway 95 95
Valine Leucine and Isoleucine Degra… 95 95
View Top Biogroups

Individual Studies

  • Effect of synthetic dietary triglycerides on liver of WT and PPARĪ±-null mice

    Mus musculus Mus musculus | RNA Expression   RNA Expression

    However, the relative importance of these transcription factors in regulation of gene expression by dietary fatty acids remains unclear. Here, we take advantage of a unique experimental design using synthetic triglycerides composed of one single fatty acid in combination with gene expression profili…

    Authors: Sanderson LM, de Groot PJ, Hooiveld GJ et al.

    Organization: Wageningen University Div. Human Nutriti…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving Fenofibrate.

View All Author iconAuthors
  • Anthony C Keech
  • Marja-Riitta Taskinen
  • FIELD study investigators
  • Anne Hiukka
  • Kerry-Anne Rye
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Solvay Pharmaceuticals
  • Merck
  • University of Florida
  • Ranbaxy Laboratories Limited
  • Pfizer
View All Affiliations icon Organizations
  • University of Sydney
  • University of Western Australia
  • University of Ioannina
  • Vanderbilt University Medical Center
  • Gachon Medical School

Clinical Trials | 138 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “Fenofibrate”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

View All NextBio Groups | 1 group

© 2009 NextBio